According to the prevailing paradigm, 1a-hydroxylation of 25-hydroxyvitamin D 3 (25(OH)D 3 ) and its analogs is a prerequisite step for their biological effects. We previously reported that 25-hydroxy-19-nor-vitamin D 3 
Introduction
2 D 3 ), the active form of vitamin D 3 , is well known to regulate cell proliferation and differentiation, bone and calcium metabolism, and immune responses (Dusso et al. 2005) . Because it can inhibit cancer cell growth, 1a,25(OH) 2 D 3 has been used to treat cancer patients in clinical trials (Masuda & Jones 2006 , Trump et al. 2010 . However, systemic administration of 1a,25(OH) 2 D 3 can cause hypercalcemia and hypercalciuria (Dusso et al. 2005) . Thus, 1a,25(OH) 2 D 3 is not suitable as a therapeutic agent for cancer treatment. Accordingly, the analogs that are less calcemic but exhibit potent anti-proliferative activity have potential as therapeutic agents. Among the analogs of 1a,25(OH) 2 D 3 , 19-nor-vitamin D compounds such as 1a, 25(OH) 2 -19-nor-D 3 ) and 1a, 25-dihydroxy-19-nor-vitamin D 2 (1a,25(OH) 2 -19-nor-D 2 ) have received most of the attention (Sicinski et al. 2007 , Glebocka et al. 2009 ). 1a,25(OH) 2 -19-nor-D analogs possess anti-proliferative activities similar to 1a,25(OH) 2 D 3 (Chen et al. 2000) , whereas the analog is less calcemic than 1a,25(OH) 2 D 3 , when administered systemically (Llach et al. 1998 , Martin et al. 1998 , Schwartz et al. 2005 .
Genomic actions of 1a,25(OH) 2 D 3 are mediated by the vitamin D receptor (VDR). On binding of the hormone to the receptor, VDR heterodimerizes with retinoid X receptor (RXR) and translocates into the nucleus (Racz & Barsony 1999 , Prufer & Barsony 2002 . The heterodimer associates with vitamin D-responsive elements in the promoter of vitamin D target genes such as 24-hydroxylase (cyp24A1; Zierold et al. 1995 , Dusso et al. 2005 . Some 19-nor-vitamin D analogs such as 1a,25(OH) 2 -19-nor-D 3 also have affinity for VDR and may act through the cognate receptor (Urushino et al. 2007 ).
Since the discovery of 1a,25(OH) 2 D 3 , 1a-hydroxylation is believed to be essential for the actions of 25-hydroxyvitamin D 3 (25(OH)D 3 ) and its analogs (Chen et al. 2000 , Dusso et al. 2005 . Hence, 25(OH)D 3 and its analogs are considered to be probioactive substances. Indeed, LNCaP, a human prostate cancer cell line, whose proliferation is refractory to 25(OH)D 3 , become responsive after transfection with the 1a-hydroxylase (cyp27B1) cDNA plasmid (Whitlatch et al. 2002) . Reduced CYP27B1 activity in human prostate cancer cells correlates with decreased susceptibility to 25(OH)D 3 -induced growth inhibition (Hsu et al. 2001) . We also reported that the growth of PZ-HPV-7 cells, an immortalized normal prostate cell line that expresses CYP27B1 (Wang et al. 2004) , could be inhibited by not only 1a,25(OH) 2 -19-nor-D 3 but also 25-hydroxy-19-nor-vitamin D 3 (25(OH)-19-nor-D 3 ; Arai et al. 2005) . This finding led us to hypothesize that 25(OH)-19-nor-D 3 exerts its anti-proliferative activity after 1a-hydroxylation mediated by CYP27B1.
The enzymatic properties of CYP enzymes involved in vitamin D 3 metabolism have been extensively studied and characterized in detail in our laboratory (Sakaki et al. 1999 . Using the reconstituted, cell-free system containing CYP24A1, CYP27A1, and CYP27B1, we have identified the metabolites of 19-nor-vitamin D 3 compounds. CYP24A1 catalyzes both C-23 and C-24 oxidation pathways and converts 1a,25(OH) 2 -19-nor-D 3 into various metabolites such as 1a, 24, 24, 25(OH) 23, 23, 25(OH) 3 -19-nor-D 3 ; Urushino et al. 2007) . We have also revealed that CYP27A1, which has subtle 25(OH)D 3 CYP27B1 activity, metabolizes 25(OH)-19-nor-D 3 into a single product, 25,26-dihydroxy-19-nor-vitamin D 3 , which has almost no affinity for VDR (Urushino et al. 2007 ). The same product was also detected as a major metabolite by CYP27B1. (Urushino et al. 2007 ). The extremely low activity toward 25(OH)-19-nor-D 3 could be explained by the docking model for CYP27B1. Although 25(OH)-19-nor-D 3 is hardly subjected to 1a-hydroxylation, it inhibited prostate cell proliferation (Arai et al. 2005) , suggesting that the anti-proliferative effects may be exerted without 1a-hydroxylation.
In this study, we studied the metabolism and action of 25(OH)-19-nor-D 3 using human prostatic epithelial PZ-HPV-7 cells. Although eight 25(OH)-19-nor-D 3 metabolites catalyzed by CYP24A1 were detected, 1a,25(OH) 2 -19-nor-D 3 was not. Nuclear translocation of VDR, transcriptional activation of CYP24A1, and inhibition of cell proliferation by 25(OH)-19-nor-D 3 were also examined to confirm our hypothesis that 25(OH)-19-nor-D 3 has anti-proliferative activity in prostate cells without 1a-hydroxylation.
Materials and methods

Chemical reagents
19-nor-Vitamin D 3 analogs (25(OH)-19-nor-D 3 , 1a,25(OH) 2 -19-nor-D 3 ) were synthesized as described previously (Arai et al. 2005) . 25(OH)D 3 was purchased from Wako Pure Chemicals Co., Ltd (Osaka, Japan).
Cell culture
The transformed PZ-HPV-7 cell line (CRL-2221) was obtained from ATCC (Manassas, VA, USA). The cell line was derived from epithelial cells of the peripheral zone of the normal prostate tissue by transfecting with HPV18 DNA. PZ-HPV-7 cells were maintained in CnT-12, which was purchased from CELLnTEC Advanced Cell Systems (Bern, Switzerland) and is a fully defined, serum and bovine pituitary extract-free formulation. All media were supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin (Invitrogen). All cells were grown in a 37 8C humidified incubator with an atmosphere of 5% CO 2 .
Metabolism of 25(OH)-19-nor-D 3 using reverse-phase HPLC and liquid chromatography tandem mass spectroscopy Cells, plated in a 35 mm dish at a density of 2!10 5 cells/well, were incubated with 1 mM 25(OH)-19-nor-D 3 for 24 h. After the incubation, metabolites were extracted using chloroform/methanol (3:1, v/v) from a mixture of cells and medium. The organic phase was recovered and dried down under reduced pressure. The resultant residue was dissolved in acetonitrile and applied to HPLC under the following conditions: column, YMCPack ODS-AM (5 mm; 4 . 6!300 mm; YMC Co., Kyoto, Japan); u.v. detection, 254 nm; flow rate, 1 . 0 ml/min; column temperature, 40 8C; mobile phase, linear gradient of 20-100% acetonitrile aqueous solution per 25 min followed by 100% acetonitrile for 20 min. Isolated metabolites from HPLC effluents were subjected to mass spectrometric analysis using a Finnegan Mat TSQ-70 with atmospheric pressure chemical ionization, positive mode. The conditions of liquid chromatography (LC) were as follows: column, reverse-phase ODS column (mBondapak C18, 5 mm; Waters, Milford, MA, USA; 6!150 mm); mobile phase, 80% methanol aqueous solution per 25 min; flow rate, 1 . 0 ml/min; and u.v. detection, 254 nm (Urushino et al. 2007 ). for 2-20 h. After the incubation, total RNA was isolated from PZ-HPV-7 using SV Total RNA Isolation System (Promega) according to the manufacturer's instructions. cDNAs were prepared using Prime Script RT reagent kit (TaKaRa, Otsu, Japan) from 1 mg total RNA. The transcript levels were determined by real-time PCR using 7500 Real-Time RT-PCR System (Applied Biosystems, Carlsbad, CA, USA) using SYBR Premix EX Taq II (TaKaRa). The PCR primers used were as follows: CYP24A1, 5 0 -CGCCGAT-TAGCAGAGCTTCAA-3 0 (forward) and 5 0 -GGTGCCTG-AGTGTAGCATCTCAAC-3 0 (reverse); VDR, 5 0 -AAGCT-GAACTTGCATGAGGAG-3 0 (forward) and 5 0 -GTCCTG-GATGGCCTCAATC-3 0 (reverse); CYP27B1, 5 0 -CTTGC-GGACTGCTCACTG-3 0 (forward) and 5 0 -CGCAGACTA-CGTTGTTCAGG-3 0 (reverse); GAPDH, 5 0 -GCACCGTC-AAGGCTGAGAAC-3 0 (forward) and 5 0 -TGTGAAGACG-CCAGTGGA-3 0 (reverse); GAPDH, 5 0 -GCACCGTCAAG-GCTGAGAAC-3 0 (forward) and 5 0 -TGTGAAGACGCC-AGTGGA-3 0 (reverse). The comparative threshold cycle values were used to determine the relative mRNA expression levels as described previously (Munetsuna et al. 2009 ). Real-time RT-PCR results were normalized by GAPDH expression levels.
Suppression of gene expression by small interfering RNAs
Duplex small interfering RNAs (siRNAs) for CYP27B1 and VDR (Stealth select RNAi) were purchased from Invitrogen. The sequences of the three sets of siRNAs were as follows: CYP27B1 siRNA: 1) 5 0 -AAAGAAUUUGGCU-CUGGGAACUGGG-3 0 and 5
0 . Each set of duplex siRNAs was transfected into PZ-HPV-7 cells for 24 h using Lipofectamine RNAiMax according to the manufacturer's instructions before treating with 19-nor-vitamin D 3 analogs.
Western blot analysis
Proteins were separated on a 10% SDS-PAGE and transferred to nitrocellulose transfer membrane (GE Healthcare, Buckinghamshire, UK). The membrane was incubated with anti-VDR rat monoclonal antibody or anti-calnexin rabbit polyclonal antibody (Abcam). Calnexin, which is one of the housekeeping proteins, was used as loading control. HRP-conjugated anti-rat IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or anti-rabbit IgG (Cell Signaling Technology, Waltham, MA, USA) was used as the secondary antibody. Protein bands were visualized using ECL Plus western blotting detection reagent (GE Healthcare). The chemiluminescence of bands for VDR or calnexin was digitized using a LAS-1000 image analyzer (Fujifilm, Tokyo, Japan).
Cell proliferation assay
MTT reagent (Wako) was used for determining the number of viable cells in proliferation. Cells were seeded in 96-well plates (1500 cells/well). Cells were treated with 25(OH)-19-nor-D 3 (0 . 1-1000 nM) or 1a,25(OH) 2 -19-nor-D 3 (0 . 1-100 nM) after preculture for 24 h. After 4 days, MTT reagent (5 mg/ml) was added to the cells. The cells were further incubated for 4 h at 37 8C and then treated with 0 . 04 M HCl/isopropanol (20 ml). Optical absorbance at 570 nm was measured using a microplate reader (Varioskan; Thermo Scientific, MA, Waltham, USA). The effect of 25(OH)D 3 (100 nM) on cell proliferation was also analyzed by counting cell numbers using counters (Invitrogen).
Statistical analysis
The statistical significance of differences in the level of mRNA for CYP24A1 induced by the 19-nor-vitamin D 3 analogs was analyzed by two-way ANOVA. The effect of the 19-nor-vitamin D 3 analogs on cell growth was analyzed by one-way ANOVA. If differences were found to be significant, the analyses were followed by post hoc t-test with Bonferroni correction. Gene suppression by siRNAs was analyzed by the Student's t-test. The criterion for significance was P!0 . 05. All results were expressed as meanGS.E.M. (Fig. 2D) , Sawada et al. 2004 , Urushino et al. 2007 . Of particular interest is the fact that no 1a,25(OH) 2 -19-nor-D 3 was detected at its retention time between M2CM3 and M4CM5 (Fig. 1) (Urushino et al. 2007) .
Results
Metabolism
Based on these data, several metabolic pathways for 25(OH)-19-nor-D 3 in PZ-HPV-7 cells are proposed as shown in Fig. 3 . It is noted that the metabolic pathways in prostate cells are quite similar to those observed in studies using recombinant human CYP24A1 expressed in Escherichia coli cells .
Translocation of VDR into the nucleus by 25(OH)-19-nor-D 3 in PZ-HPV-7 cells
It has been reported that the activated VDR heterodimerizes with RXR and translocates into the nucleus (Racz & Barsony 1999) . Thus, we examined the nuclear translocation of VDR induced by 25(OH)-19-nor-D 3 and 1a,25(OH) 2 -19-nor-D 3 . In Fig. 4 , the left panels show nuclear import of VDR after incubation with 1 nM 1a,25(OH) 2 -19-nor-D 3 for 0-90 min. At 0 min, VDR appeared to be dispersed all over the cytoplasm. Thereafter, time-dependent nuclear translocation of VDR was observed at 30-60 min. Finally, at 90 min, most of VDR was localized in the nucleus. Rapid nuclear translocation of VDR was also observed by the addition of 100 nM 25(OH)-19-nor-D 3 (Fig. 4, right panels) . Both 25(OH)-19-nor-D 3 and 1a,25(OH)-19-nor-D 3 showed similar time-dependent translocation (Fig. 4) , suggesting that 25(OH)-19-nor-D 3 directly binds to VDR as a ligand to induce nuclear translocation without converting to its 1a-hydroxylated metabolite. 
25(OH)-19
-nor-D 3 (10 and 100 nM) for 2-20 h. CYP24A1 mRNA was quantified by real-time RT-PCR. As expected, a significant increase of CYP24A1 mRNA level was observed at 2 h (Fig. 5, left panel) . The CYP24A1 mRNA level was increased as high as 700 times with 10 nM 1a,25(OH) 2 -19-nor-D 3 at 5 h and then decreased. The CYP24A1 mRNA level was also increased 150 and 800 times with 10 and 100 nM 25(OH)-19-nor-D 3 , respectively, in the same time-dependent manner as 1a,25(OH) 2 -19-nor-D 3 .
Effect of 25(OH)-19-nor-D 3 on PZ-HPV-7 cell growth
It has been demonstrated that VDR activation is required for growth inhibition of prostate cell (Miller et al. 1992) Fig. 7A and B, middle panels), which is not statistically different from the non-transfected cells ( Fig. 7A and B left panels). However, transfection with VDR siRNA abolished the anti-proliferation activity of both 25(OH)-19-nor-D 3 and 1a,25(OH) 2 -19-nor-D 3 ( Fig. 7A and B, right panels).
Transfection with non-silencing siRNA did not affect cell growth compared to non-transfected cells. We confirmed that expression of CYP27B1 and VDR mRNA was significantly reduced compared with non-silencing siRNA-transfected cells (Fig. 7C) . We also confirmed that VDR protein level was decreased by VDR siRNA transfection (Fig. 7C right panel) . However, we have failed to detect CYP27B1 protein by western blot probably due to its low expression level in PZ-HPV-7 cells. Alternatively, we analyzed the effect of CYP27B1 siRNA transfection on the enzyme activity. We revealed that CYP27B1 enzyme activity using [H 3 ]-25(OH)D 3 was reduced to about 20% with the CYP27B1 siRNA transfection in PZ-HPV-7 cells (data not shown).
These results strongly support our conclusion that 25(OH)-19-nor-D 3 induces cell growth inhibition mediated through VDR in PZ-HPV-7 cells without its conversion to 1a,25(OH) 2 -19-nor-D 3 by CYP27B1.
Discussion
A large number of vitamin D analogs have been synthesized and studied for potential clinical application (Binderup et al. 1991 , Bouillon et al. 1995 , Yamada et al. 2003 , Posner et al. 2010 . Among vitamin D 3 analogs, it has been reported that A-ring-modified 19-nor-vitamin D compounds have unique biological activity and can alter the VDR-coactivator interaction, resulting in selective potentiation of the transcriptional function (Kittaka et al. 2000 , Konno et al. 2000 , Suhara et al. 2001 , Ono et al. 2003 , Arai et al. 2005 . For example, 1a,25(OH) 2 -19-nor-D 2 (also called paricalcitol or Zemplar) was approved by the Food and Drug Administration for the treatment of secondary hyperparathyroidism and clinical trials have shown that the compound is non-calcemic (Llach et al. 1998 , Martin et al. 1998 , Schwartz et al. 2005 . 19-nor-Vitamin D 3 0 min 1α,25(OH) 2 -19-nor-D 3 ( 1 derivatives are also believed to be useful for prostate cancer chemoprevention and therapy (Chen et al. 2000 , Rashid et al. 2001 , Chen & Holick 2003 , Arai et al. 2005 .
In this study, we clearly demonstrated that not only 1a,25(OH) 2 -19-nor-D 3 but also 25(OH)-19-nor-D 3 has biological activity in human prostate cells. We would like to emphasize that a detailed metabolic analysis was linked to reveal genomic actions of the vitamin D analogs in this study. Based on our previous studies, all the metabolites detected in PZ-HPV-7 cells were produced by CYP24A1 catalysis. It should be noted that 1a,25(OH) 2 -19-nor-D 3 was not found, which is consistent with our previous findings using a cell-free reconstituted system showing that CYP27B1 and CYP27A1 hardly converted 25(OH)-19-nor-D 3 into 1a,25(OH) 2 -19-nor-D 3 (Urushino et al. 2007) . The absence of a methylene group at C-19 position may prevent the binding of 19-nor compounds to the substrate-binding pocket of CYP27B1 without affecting their binding to CYP24A1. Generally, metabolites produced by CYP24A1 are likely to have reduced affinity for VDR compared with the substrate (Bouillon et al. 1995) . Therefore, it seems likely that no metabolites more active than 25(OH)-19-nor-D 3 were produced in PZ-HPV-7 cells. In this study, we concluded that 25(OH)-19-nor-D 3 itself exhibits its biological activity via binding to VDR, although the affinity of the compound for VDR is much lower than 1a,25(OH) 2 D 3 . Our previous study demonstrated that the affinity of 1a,25(OH) 2 -19-nor-D 3 is w4% of 1a,25(OH) 2 D 3 (Urushino et al. 2007 ). In addition, based on the fact that the affinity of 25(OH)D 3 is about 500 times less than that of 1a,25(OH) 2 D 3 (Bouillon et al. 1995) , the affinity of 25(OH)-19-nor-D 3 appears to be about 100 times less than that of 1a,25(OH) 2 -19-nor-D 3 . Thus, the major reason why 25(OH)-19-nor-D 3 requires 10-100 times higher concentration than 1a,25(OH) 2 -19-nor-D 3 to achieve the same effects may be due to its much lower affinity for VDR comparing to 1a,25(OH) 2 -19-nor-D 3 .
It has been demonstrated that VDR translocates into the nucleus in a hormone-dependent manner (Racz & Barsony 1999) . We examined the time course of VDR nuclear transport induced by 19-nor-vitamin D 3 analogs. Immunofluorescence analysis clearly demonstrated that 25(OH)-19-nor-D 3 acted as quickly as 1a,25(OH) 2 -19-nor-D 3 . These results lead us to conclude that 25(OH)-19-nor-D 3 binds to VDR directly, without being subjected to 1a-hydroxylation.
Nuclear translocation of VDR into the nucleus within 90 min could explain a significant increase in CYP24A1 mRNA level at 2 h. The time-dependent changes of (Miller et al. 1992 , Chen et al. 2000 , Chen & Holick 2003 . In this study, we confirmed that not only 1a,25(OH) 2 -19-nor-D 3 but also 25(OH)-19-nor-D 3 inhibited cell growth. The antigrowth effect of 25(OH)-19-nor-D 3 and 1a,25(OH) 2 -19-nor-D 3 was attenuated by knock down of VDR gene, implying that the effect depends on VDR. However, it should be noted that the anti-proliferative activity of 25(OH)-19-nor-D 3 was not affected by knock down of cyp27B1 gene. Taken together, we conclude that the mode of 25(OH)-19-nor-D 3 action derived from this study is VDR dependent but CYP27B1 independent.
Anti-proliferative activity of vitamin D 3 and its analogs is well known to be correlated with an increase in the levels of the cyclin-dependent kinase inhibitors (CKI) such as p21 waf1,CIP1 and p27
Kip1
, leading to a profound decrease in cyclin-dependent kinase 2 activity and inhibition of cell cycle progression from G 1 to S phase in LNCaP prostate cancer cells (Yang & Burnstein 2003 Based on the present results, we propose a novel action model of 25(OH)-19-nor-D 3 as shown in Fig. 8 . This model shows a direct action of 25(OH)-19-nor-D 3 as a ligand of VDR and differs from a classical model that 25(OH)D 3 analogs exert its biological function after 1a-hydroxylation by CYP27B1. It should be noted that the model in Fig. 8 resembles the action model proposed by Tuohimaa's group, suggesting a unique biological activity of 25(OH)D 3 as a ligand of VDR in human prostate cells (Lou et al. 2004 (Lou et al. , 2010 . Recently, Deluca et al. (2011) also suggested a direct action of 25(OH)D 3 as a VDR ligand in Cyp27b1 knockout mice. In this study, we also examined the effect of 25(OH)D 3 . The addition of 100 nM 25(OH)D 3 to no siRNA-and CYP27B1 siRNA-transfected PZ-HPV-7 cells decreased cell growth to 37 and 45%, respectively. However, VDR knock down canceled the anti-proliferative activity of 25(OH)D 3 . These results strongly suggest a direct action of 25(OH)D 3 as a VDR ligand. The genomic actions of the vitamin D compounds might not require the hydroxylation at C-1 position in human prostate cells. As CYP27A1 and CYP2R1 have been shown to be expressed in prostate tissue (Flanagan et al. 2006) 
